Clinical Medicine: Endocrinology and Diabetes: Abnormality of Serum Lipids are Independently Associated with Increased Serum Calcium Level in the Adult Newfoundland Population

2009 ◽  
Vol 2 ◽  
pp. CMED.S2974
Author(s):  
Aaron Kennedy ◽  
Sudesh Vasdev ◽  
Edward Randell ◽  
Ya-Gang Xie ◽  
Kristian Green ◽  
...  
Keyword(s):  
Vitamin D ◽  
Total Cholesterol ◽  
Serum Calcium ◽  
Serum Lipids ◽  
Density Lipoprotein ◽  
Confounding Factors ◽  
Menopausal Women ◽  
25 Oh Vitamin D ◽  
Positive Correlations ◽  
Post Menopausal

Some epidemiological evidence shows a link between abnormality of lipid profiles and variations in serum calcium. However, it is unknown whether this association resulted from confounding factors. The present study was designed to investigate the relationship between serum lipids and calcium. Serum calcium was corrected for albumin. Major confounding factors including age, gender, medications, menopause, parathyroid hormone (PTH) and 25-OH-vitamin D status were controlled in analyses. A total of 1907 adult subjects from the province of Newfoundland and Labrador (NL), Canada participated in the study. Significant positive correlations were detected between serum total cholesterol and high density lipoprotein-cholesterol (HDL-c) with variations of serum Ca++ in both genders (p < 0.05–0.0001). Significant positive correlations were additionally detected between triglycerides (TG) and low density lipoprotein-cholesterol (LDL-c) with Ca++ in women only (p < 0.0001) in partial correlation analyses. Similar significant results were detected in both females and males not taking any medication. Analyses were performed based on menopausal status as well. Significant correlations were seen in both pre- and post-menopausal women but higher correlation coefficients were observed in pre-menopausal women as compared to post-menopausal women. Subjects with low calcium levels had the lowest concentration of total cholesterol, TG, HDL-c and LDL-c, while subjects with high calcium levels had the highest concentration of all four markers in women. The significant associations between cholesterol, TG and LDL-c and serum Ca++ remained after calcium was adjusted for 25-OH-vitamin D and PTH. Our results indicate that the abnormality of serum lipid profiles are significantly correlated with altered serum Ca++ levels independent of age, obesity status, medication, phosphorus, magnesium, 25-OH-vitamin D and PTH.

Association between vitamin D and bone mineral density in post-menopausal women with metabolic syndrome

2015 ◽  
Vol 22 (1) ◽  
pp. 7-14
Author(s):  
Jolanta Dadonienė ◽  
Alma Čypienė ◽  
Egidija Rinkūnienė ◽  
Jolita Badarienė ◽  
Jelizaveta Burca ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Metabolic Syndrome ◽  
Vitamin D ◽  
Bone Mineral ◽  
Density Lipoprotein ◽  
Serum Glucose ◽  
Mineral Density ◽  
Normal Bone Mineral Density ◽  
Menopausal Women ◽  
Post Menopausal

Background. The aim of this study was to identify the relation between vitamin D level and mineral bone density in post-menopausal women with metabolic syndrome. Materials and methods. This study included 100 post-menopausal women at age between 50 and 65 with metabolic syndrome. All participants underwent anthropometric measurements. Laboratory tests were performed to determine lipid profile, serum glucose, creatinine, C-reactive protein, vitamin D (25(OH) D), ionized calcium concentration and urine albumin / creatinine ratio. Bone mineral density of the lumbar spine (L1– L4) and total hip was measured by dual-energy X-ray absorptiometry. Results. According to the vitamin D concentration level in the blood all women were divided into four groups: the average failure was observed in 57%, mild failure in 33%, severe failure in 5%; and only 5% of women had normal vitamin levels. The mean 25(OH) D level was 47.40  ±  16.91  nmol/l. According to bone densitometry we found that 77% of all participants had normal bone mineral density, 22% had osteopenia and 5% were diagnosed with osteoporosis. No correlation was found between bone mineral density and 25(OH)  D levels. We found a weak positive correlation between high density lipoprotein cholesterol and 25(OH) D (r = 0.3, p 

scholarly journals Reference intervals for serum lipids and prevalence of dyslipidaemia in 6–12-year-old children: The Health Oriented Pedagogical Project (HOPP)

2018 ◽  
Vol 46 (21_suppl) ◽  
pp. 21-27 ◽  
Author(s):  
Martin Frank Strand ◽  
Per Morten Fredriksen ◽  
Ole Petter Hjelle ◽  
Morten Lindberg
Keyword(s):  
Total Cholesterol ◽  
Serum Lipids ◽  
Venous Blood ◽  
Elevated Serum ◽  
Density Lipoprotein ◽  
Hdl Cholesterol ◽  
Reference Intervals ◽  
Age And Gender ◽  
Norwegian Population ◽  
And Gender

Aims: Elevated serum lipid concentrations in childhood are thought to be risk factors for the development of cardiovascular disease later in life. The present study aims to provide age- and gender-related reference intervals for total cholesterol (TC), high-density lipoprotein (HDL) cholesterol, and non-HDL cholesterol in healthy school children. We also investigated the prevalence of dyslipidaemia using the published criteria for these biomarkers. Methods: Venous blood and anthropometric data were collected from 1340 children in the HOPP study, aged between 6 and 12 years. Age- and gender-related reference intervals (2.5th and 97.5th percentiles) were established according to the IFCC recommendations, using the software RefVal 4.10. Results: Gender differences were observed for total cholesterol and non-HDL cholesterol, but not for HDL cholesterol. Age differences were observed for total cholesterol. The reference intervals were in the range of 3.1–5.9 mmol/L for total cholesterol, 1.0–2.4 mmol/L for HDL cholesterol and 1.4–4.2 mmol/L for non-HDL cholesterol. Dyslipidaemia prevalence was as follows: increased TC 9.6%, decreased HDL 1.6%, and increased non-HDL 5.6%. Conclusions: Age- and gender-related reference intervals in a Norwegian population are similar to those reported in other countries. The prevalence of dyslipidaemia among Norwegian children is significant, emphasising the importance of appropriate reference intervals in clinical practice.

Evaluation of the Relationship between Vitamin D Deficiency and Atherogenic Factors in Diabetic Patients with Metabolic Syndrome

2021 ◽  
Author(s):  
Leila Akbarbaglu ◽  
Elham Nozari Mirarkolaei ◽  
Massoumeh Hotelchi ◽  
Abbas Khonakdar-Tarsi ◽  
Mahboobeh Ghanbari ◽  
...  
Keyword(s):  
Metabolic Syndrome ◽  
Vitamin D ◽  
Serum Level ◽  
Total Cholesterol ◽  
Vitamin D3 ◽  
Atherogenic Index ◽  
Control Group ◽  
Diabetic Patients ◽  
Significant Difference ◽  
25 Oh Vitamin D

Introduction: Metabolic syndrome includes a range of disorders that increase the risk of cardiovascular disease and diabetes mellitus. In this study, we examined the serum level of vitamin D3 in diabetic individuals with metabolic syndrome compared with non-diabetic individuals without metabolic syndrome and the association of serum vitamin D3 levels with metabolic syndrome and atherogenic factor (LDL/HDL). Material and Methods: In a case-control study, we included 110 women with metabolic syndrome according to ATP III criteria and 127 healthy women as a control group. Serum concentration of total cholesterol, LDL-C, FBS, HDL-C and serum triglyceride determined by enzymatic method and colorimetric and, serum level 25-(OH) vitamin D determined by ELISA. Results: It was found that the two healthy and metabolic groups were significantly different in terms of total cholesterol levels, LDL and triglyceride levels, HDL, VLDL, FBS, atherogenic index (LDL/HDL) and vitamin D levels (p<0.05). All participants in the control group and the patient and the whole study population were divided into two categories of insufficient and sufficient based on their measured serum concentrations of 25-(OH) vitamin D. There was a significant difference between the group with insufficient levels of vitamin D in comparison with the group with sufficient levels of vitamin D in terms of total cholesterol, LDL and triglyceride levels, HDL, VLDL, FBS and atherogenic index (LDL/HDL) (p=0.000). Conclusion: The present results showed that there is a significant relationship between level 25-(OH) D and atherogenic index (LDL/HDL) and the incidence of metabolic syndrome.

scholarly journals Calcium and vitamin D in post menopausal women

2013 ◽  
Vol 17 (9) ◽  
pp. 618 ◽  
Author(s):  
Sameer Aggarwal ◽  
Nityanand
Keyword(s):  
Vitamin D ◽  
Menopausal Women ◽  
Post Menopausal

scholarly journals Correlation of mandibular radiomorphometric indices with serum calcium and serum estradiol in pre- and post-menopausal women

2017 ◽  
Vol 8 (1) ◽  
pp. 53 ◽  
Author(s):  
LinaGovind Chandak ◽  
VidyaKrushnarao Lohe ◽  
RahulR Bhowate ◽  
KrushnaP Gandhi ◽  
NehaV Vyas
Keyword(s):  
Serum Calcium ◽  
Serum Estradiol ◽  
Menopausal Women ◽  
Post Menopausal

Lipoproteins during oral and cutaneous administration of oestradiol-17β to menopausal women

1982 ◽  
Vol 101 (4) ◽  
pp. 597-602 ◽  
Author(s):  
Lars Fåhraeus ◽  
Ulf Larsson-Cohn ◽  
Lars Wallentin
Keyword(s):  
Low Density Lipoprotein ◽  
Density Lipoprotein ◽  
Clinical Results ◽  
Point Of View ◽  
Clinical Effects ◽  
Low Density ◽  
Oestradiol Treatment ◽  
Menopausal Women ◽  
Post Menopausal ◽  
Cutaneous Administration

Abstract. Thirty-eight post-menopausal women were randomly allocated to substitution treatment with either oestradiol-17β orally (2–4 mg) or cutaneously (3 mg). The concentrations of cholesterol (C), triglycerides (TG) and phospholipids were determined in the high density lipoprotein (HDL)-, the low density lipoprotein (LDL)- and the very low density lipoprotein (VLDL)- fractions twice before medication and after 2, 4 and 6 months of treatment. Both treatments gave satisfactory clinical results. Oral doses increased the HDL and decreased the LDL thus raising the HDL-C/LDL-C ratio. The higher oral dose also increased the TG concentration. Cutaneous oestradiol gave only minimal changes of the lipoproteins. The lipoprotein changes observed during treatment with oral oestradiol might reduce the risk for atherosclerotic disease. Therefore, from a lipoprotein point of view, oral oestradiol treatment probably could be considered beneficial. The cutaneous oestradiol treatment had comparable clinical effects without any influence on the lipoprotein pattern.

Renal osteodystrophy

2013 ◽  
pp. 1274-1282
Author(s):  
Thomas Bardin ◽  
Tilman Drüeke
Keyword(s):  
Vitamin D ◽  
Bone Turnover ◽  
Serum Calcium ◽  
Renal Osteodystrophy ◽  
Serum Phosphorus ◽  
Osteitis Fibrosa ◽  
Alkaline Phosphatases ◽  
Calcium Phosphorus ◽  
Turnover Markers ◽  
25 Oh Vitamin D

Renal osteodystrophy (ROD) is a term that encompasses the various consequences of chronic kidney disease (CKD) for the bone. It has been divided into several entities based on bone histomorphometry observations. ROD is accompanied by several abnormalities of mineral metabolism: abnormal levels of serum calcium, phosphorus, parathyroid hormone (PTH), vitamin D metabolites, alkaline phosphatases, fibroblast growth factor-23 (FGF-23) and klotho, which all have been identified as cardiovascular risk factors in patients with CKD. ROD can presently be schematically divided into three main types by histology: (1) osteitis fibrosa as the bony expression of secondary hyperparathyroidism (sHP), which is a high bone turnover disease developing early in CKD; (2) adynamic bone disease (ABD), the most frequent type of ROD in dialysis patients, which is at present most often observed in the absence of aluminium intoxication and develops mainly as a result of excessive PTH suppression; and (3) mixed ROD, a combination of osteitis fibrosa and osteomalacia whose prevalence has decreased in the last decade. Laboratory features include increased serum levels of PTH and bone turnover markers such as total and bone alkaline phosphatases, osteocalcin, and several products of type I collagen metabolism products. Serum phosphorus is increased only in CKD stages 4-5. Serum calcium levels are variable. They may be low initially, but hypercalcaemia develops in case of severe sHP. Serum 25-OH-vitamin D (25OHD) levels are generally below 30 ng/mL, indicating vitamin D insufficiency or deficiency. The international KDIGO guideline recommends serum PTH levels to be maintained in the range of approximately 2-9 times the upper normal normal limit of the assay and to intervene only in case of significant changes in PTH levels. It is generally recommended that calcium intake should be up to 2 g per day including intake with food and administration of calcium supplements or calcium-containing phosphate binders. Reduction of serum phosphorus towards the normal range in patients with endstage kidney failure is a major objective. Once sHP has developed, active vitamin D derivatives such as alfacalcidol or calcitriol are indicated in order to halt its progression.

Prevalence and Correction of 25(OH) Vitamin D Deficiency in Peritoneal Dialysis Patients

2005 ◽  
Vol 25 (4) ◽  
pp. 362-366 ◽  
Author(s):  
Nirav Shah ◽  
Judith Bernardini ◽  
Beth Piraino
Keyword(s):  
Vitamin D ◽  
Peritoneal Dialysis ◽  
Calcium Phosphate ◽  
Vitamin D Deficiency ◽  
Muscle Weakness ◽  
Serum Calcium ◽  
Bone Pain ◽  
Vitamin D Levels ◽  
Before And After ◽  
25 Oh Vitamin D

Background Peritoneal dialysis (PD) patients are at risk for 25(OH) vitamin D deficiency due to effluent loss in addition to traditional risk factors. Objectives To measure 25(OH) vitamin D deficiency in prevalent PD patients, to evaluate a replacement dose, and to determine the effects of correction. Methods 25(OH) vitamin D levels were drawn on prevalent PD patients. Patients deficient in 25(OH) vitamin D were given ergocalciferol, 50 000 IU orally once per week for 4 weeks. Patients scored muscle weakness, bone pain, and fatigue on a scale of 0 (none) to 5 (severe). Serum calcium, phosphate, parathyroid hormone (PTH), and 25(OH) vitamin D, and 1,25(OH)2 vitamin D levels were obtained before and after treatment. Results 25(OH) vitamin D levels were measured in 29 PD patients. Deficiency (<15 ng/mL) was found in 28/29 (97%); 25/29 (86%) had undetectable levels (<7 ng/mL). One course of ergocalciferol corrected the deficiency in all but 1 patient, who required a second course. Scores for muscle weakness and bone pain fell from pre- to posttreatment ( p < 0.001). 1,25(OH)2 vitamin D levels rose post ergocalciferol (from 20 to 26 pg/mL, n = 20, p = 0.09). Serum calcium, phosphate, and PTH levels did not change with ergocalciferol. Conclusions Most PD patients had marked 25(OH) vitamin D deficiency, which was readily and safely corrected with one course of 50000 IU ergocalciferol, having no effect on serum calcium, phosphorus, or PTH, but complaints of muscle weakness and bone pain decreased. A prospective, placebo-controlled double-blinded study is needed to determine whether replacement of 25(OH) vitamin D is beneficial in PD patients.

Late Onset Hypocalcemic Seizures in Formula-Fed, Vitamin D Deficient Babies: Revisited

2020 ◽  
Vol 34 (1-2) ◽  
pp. 15-18
Author(s):  
Umar Amin Qureshi ◽  
Abdus Sami Bhat ◽  
Muzaffar Jan ◽  
Uruj Qureshi
Keyword(s):  
Vitamin D ◽  
Breast Feeding ◽  
Serum Calcium ◽  
Late Onset ◽  
Response To Treatment ◽  
Total Serum ◽  
Total Serum Calcium ◽  
Vitamin D Levels ◽  
Calcium Phosphorus ◽  
25 Oh Vitamin D

Purpose: Late onset neonatal hypocalcemia (LNH) is defined as hypocalcemia detected after day 3 of life. Its occurrence in babies fed with cow’s milk is well understood. Since the advent of modern-day formulas, the incidence has however decreased. Methods: A prospective descriptive study (January 2017 to December 2017) of LNH seizures in neonates was conducted. LNH was defined as the total serum calcium of less than 7 mg/dL in preterm or less than 8 mg/dL in term newborns after 72 h of life. Results: 14 neonates were presented with myoclonic and focal seizures due to late hypocalcemia. All were formula fed. Their mean serum calcium, phosphorus, alkaline phosphatase, magnesium, 25-OH vitamin D, intact PTH levels were 4.93 mg/dL, 9.19 mg/dL, 244 U/L, 1.2 mg/dL, 30 nmol/L, 38.6 pg/mL, respectively. Mean maternal vitamin D levels were 43 nmol/L. Mean hospital stay was 4 days. Clinical response to treatment was brisk in those who were able to shift to total breast feeding early. Conclusions: LNH in formula-fed and vitamin D deficient babies is not uncommon. Emphasis should be laid on exclusive breast feeding even in vitamin D deplete mothers. However, mothers at risk should be supplemented with vitamin D during pregnancy.

Sign in / Sign up

Export Citation Format

Share Document